- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.02. | 59 NORTH COMMUNICATIONS: Affibody's licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement | 1 | Cision News | ||
| 17.02. | Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 | 2 | Benzinga.com | ||
| 17.02. | Rallybio Reports Positive Data For RLYB116 Phase 1 Study | 1 | RTTNews | ||
| 03.02. | Rallybio announces one-for-eight reverse stock split effective Feb 6 | 3 | Investing.com | ||
| 03.02. | Rallybio Corporation Announces Reverse Stock Split of Common Stock | 135 | Business Wire | NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) will effect a one-for-eight reverse stock split of its issued and outstanding common stock. Stockholders of Rallybio approved an... ► Artikel lesen | |
| 29.01. | Rallybio Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 06.11.25 | Rallybio Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| RALLYBIO Aktie jetzt für 0€ handeln | |||||
| 06.11.25 | Rallybio Corp - 8-K, Current Report | - | SEC Filings | ||
| 25.09.25 | Rallybio completes first cohort dosing in RLYB116 C5 inhibitor study | 8 | Investing.com | ||
| 21.09.25 | Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances | 21 | Insider Monkey | ||
| 11.09.25 | Rallybio: $12.5 Million Equity Milestone Payment Received | 1 | pulse2.com |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 91,20 | -2,25 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| AMGEN | 327,55 | -0,30 % | Is Amgen Stock Outperforming the Dow? | ||
| NOVAVAX | 8,073 | -5,89 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| BIOGEN | 160,00 | -1,45 % | WONBIOGEN Co., Ltd: Won BioGen Accelerates Global Market Expansion with Advanced Moist Wound Care Technology | SEOUL, South Korea, Feb. 24, 2026 /PRNewswire/ -- Medical device manufacturer Won BioGen (CEO Kim Won-il) is accelerating its global market expansion based on its advanced moist wound care... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,500 | -4,11 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| MAINZ BIOMED | 0,748 | +2,78 % | Mainz BioMed NV: Mainz Biomed to Present at the Pancreatic Cancer Session at Digestive Disease Week, Demonstrating Effectiveness of mRNA Biomarkers in Blood Samples | ||
| INTELLIA THERAPEUTICS | 10,845 | -6,99 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates | HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites... ► Artikel lesen | |
| TEMPUS AI | 43,000 | -4,87 % | Tempus AI Quartalszahlen: 90 % Umsatzplus bestätigen KI-Trend in der Medizin | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das vierte Quartal 2025 veröffentlicht und ein rasantes Umsatzwachstum verzeichnet. Tempus AI -... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,300 | -1,48 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Full Year 2025 Financial Results and Provides Business Update | -Full year 2025 ORLADEYO® net revenue of $601.8 million (+38% y-o-y; +43% y-o-y excluding European ORLADEYO revenue following the sale of the European ORLADEYO business to Neopharmed Gentili S.p.A.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 50,34 | -3,64 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,155 | -0,18 % | Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
| EXELIXIS | 36,950 | -0,94 % | 3 Reasons Exelixis Stock Could Deliver Market-Beating Returns Over the Next Decade | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,386 | -2,85 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| CARDIOL THERAPEUTICS | 0,920 | +6,11 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - February 25, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing... ► Artikel lesen | |
| VAXART | 0,560 | -11,11 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
RALLYBIO CORPORATION gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +10,47 % bei einem Aktienkurs von 7,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RALLYBIO CORPORATION finden Sie auf Wallstreet Online.